A case of erectile dysfunction and risk factors for coronary artery disease

International Journal of Impotence Research

Volumn 17, Issue SUPPL. S1, 2005, Pages

  Kloner, R A ^a,b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angina pectoris; Cardiovascular risk factors; Erectile dysfunction; Hypertension; Phosphodiesterase inhibitors; Princeton Consensus Conference Guidelines; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NITRIC OXIDE DONOR; ORGANIC NITRATE; PHOSPHODIESTERASE V INHIBITOR; PROCAINAMIDE; QUINIDINE; SILDENAFIL; SOTALOL; TADALAFIL; THIAZIDE DIURETIC AGENT; VARDENAFIL;

ANGINA PECTORIS; ARTICLE; BACKACHE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ERECTILE DYSFUNCTION; GLUCOSE INTOLERANCE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; INTERMITTENT CLAUDICATION; LIFESTYLE; MYALGIA; OBESITY; ORTHOSTATIC HYPOTENSION; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QT PROLONGATION; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; TREATMENT CONTRAINDICATION; WEIGHT REDUCTION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; ENZYME INHIBITORS; EXERCISE; GUIDELINES; HUMANS; HYPERTENSION; IMPOTENCE; MALE; MIDDLE AGED; OBESITY; PIPERAZINES; RISK FACTORS;

EID: 30044439346     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901423     Document Type: Article

References (50)

1. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of Massachusetts male aging study. J Urol 1994; 151: 54-61.
2. Feldman HA et al. Erectile dysfunction and coronary risk factors: prospective results from Massachusetts male aging study. Prev Med 2000; 30: 328-338.
3. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576-582.
4. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 y later. The Rancho Bernardo study. J Am Coll Cardiol 2004; 43: 1405-1411.
5. Kaiser DR et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179-184.
6. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-253.
7. Grimm Jr RH et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of mild hypertension study (TOMHS). Hypertension 1997; 29: 8-14.
8. Wassertheil-Smoller S et al. Effects of antihypertensives on sexual function and quality of life. The TAIM Study. Ann Intern Med 1991; 114: 613-620.
9. Llisterri JL et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336-341.
10. Kostis JB et al. Sexual dysfunction and cardiac risk: the 2nd princeton consensus conference. Am J Cardiol 2005; 96: 313-321.
11. DeBusk R et al. Management of sexual dysfunction in patients with cardiovascular disease: The princeton consensus panel. Am J Cardiol 2000; 86: 175-181.
12. Derby CA et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302-306.
13. Pourmand G et al. Do cigarette smokers with erectile dysfunction benefit from stopping? A prospective study. BJU Int 2004; 94: 1310-1313.
14. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92: 9M-18M.
15. Kloner RA. Cardiovascular effects of the three phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149-3155.
16. Cheitlin MD et al. Use of sildenafil in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273-282.
17. Webb DJ et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Card 1999; 83: 21C-28C.
18. Webb DJ et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36: 25-31.
19. Kloner RA et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42: 1855-1860.
20. Kloner RA. Commentary on 'Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. J Sex Med 2005; 2: 424-425.
21. DeBusk RF. Sexual activity in patients with angina. JAMA 2003; 290: 3129-3132.
22. Sildenafil prescribing information. Pfizer. NY, NY, 2004.
23. Product Monograph for Levitra® (vardenafil HCL). Bayer Health Care, Glaxo SmithKline, 2003.
24. Cialis (tadalafil) prescribing information, Lilly ICOS LLC, Indianapolis, Indiana and Bothell: Washington, DC 2003.
25. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92: 37M-46M.
26. Padma-Nathan H. Sildenafil citrate (Viagra) and erectile dysfunction: a comprehensive four year update on efficacy, safety, and management options. Urology 2002; 60(Suppl): 1-90.
27. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra®) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clinic Pract 2003; 57: 597-600.
28. Kloner RA et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE5 inhibitor in patients with erectile dysfunction: analysis of five-controlled clinical trials. Pharmacol Ther 2002; 22: 1371.
29. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92(Suppl): 37M-346M.
30. Shakir SAW et al. Cardiovascular events in users of sildenafil. Results from first phase of prescription event monitoring in England. BMJ 2001; 322: 651-652.
31. Boshier A, Wilton LV, Shakir SAW. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004; 93: 796-801.
32. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89: 1331-1334.
33. Fox KM, et al., on behalf of the CAESAR 1 (Clinical American and European Studies of Angina And Revascularization) Investigators. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003; 24: 2206-2212.
34. Arruda-Olson AM et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287: 719-725.
35. Thadani U et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006-2012.
36. Patterson D et al. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Circulation 2002; 106(Suppl II): II-330.
37. Hermann HC et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622-1626.
38. Morganroth J et al. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004; 93: 1378-1383.
39. Jackson G et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C.
40. Zusman RM et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35C-44C.
41. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl 2002; 4(Suppl H): H32-H47.
42. Kloner RA et al. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled trials. J Am Coll Cardiol 2003; 41(Suppl A): 276A-277A.
43. Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000; 18: 1865-1869.
44. Kloner RA, et al., for the Sildenafil Study Group. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001; 14: 70-73.
45. Pickering TG et al. Safety of Viagra (Sildenafil Citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treatments. American J Hypertension 2002; 15(Suppl 1): A55-A56.
46. Padma-Nathan H et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Presented at the American Society of Hypertension 17th Annual Scientific Meeting. New York, NY, 2002.
47. Rohde G, Jordan P. Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy. (abstr.). Pharmacotherapy 2002; 202: 418.
48. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92(Suppl): 47M-57M.
49. Kloner RA et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and the two alpha blockers: doxazosin, and tamsulosin in healthy normotensive men. J Urol 2004; 172: 1935-1940.
50. Auerbach S et al. Coadministered vardenafil (for erectile dysfunction) and tamsulosin do not induce hypotension in patients with benign prostatic hypertrophy. Am J Hypertens 2004; 17: 16A.